About Us - Corporate Officers
Ivan Gergel,
M.D., was appointed Executive Vice President, Research &
Development, in April 2008. Dr. Gergel has full responsibility
for all of the company’s R&D activities, including direct
supervision of clinical research, pre-clinical R&D, medical
affairs, marketed product development support, regulatory
affairs, project management and drug safety and surveillance.
From May 2005 until March 2008, Dr. Gergel was Senior Vice
President of Scientific Affairs and President of the Forest
Research Institute of Forest Laboratories Inc., managing over
900 physicians, scientists and staff at the Research Institute.
Prior to that, Dr. Gergel served as Vice President and Chief
Medical Officer at Forest and Executive Vice President of the
Forest Research Institute. He joined Forest in 1998 as Executive
Director of Clinical Research following nine years at SmithKline
Beecham, and was named Vice President of Clinical Development
and Clinical Affairs in 1999.
David P. Holveck was appointed
President, Chief Executive Officer, and a Director of Endo in April
2008. Prior to joining Endo, Mr. Holveck was President of Johnson &
Johnson Development Corporation and Vice President, Corporate
Development of Johnson & Johnson since 2004. Mr. Holveck joined
Johnson & Johnson as a company Group Chairman in 1999, following the
acquisition of Centocor, Inc., by Johnson & Johnson. Mr. Holveck
was Chief Executive Officer of Centocor, Inc., at the time of the
acquisition. Mr. Holveck joined Centocor in 1983 and progressed
through various executive positions. In 1992, he assumed the role of
President and Chief Operating Officer and later that year was named
President and Chief Executive Officer. Prior to joining Centocor, he
held positions at General Electric Company, Corning Glass Works, and
Abbott Laboratories. Mr. Holveck is a member of the Board of
Trustees for the Fund for West Chester University and the Board of
Directors of the Eastern Technology Council. Effective April 7,
2008¸ Mr. Holveck was appointed to the board of directors of Light
Sciences Oncology, Inc., and effective April 14, 2008, he was
appointed to the board of directors of Tengion Inc.
Joyce N. LaViscount
has served as Chief Accounting Officer and Vice President
of Finance at Endo since August
2006. Prior to joining Endo in April 2004 as the Vice President of
Financial Analysis and Planning, Joyce held positions of increasing
scope and responsibility at Pfizer, Inc. (formerly Pharmacia
Corporation) in Peapack, New Jersey, in both the pharmaceutical and
consumer healthcare groups. Prior to joining Pharmacia, Ms.
LaViscount held various positions at Bristol-Myers Squibb Company in
Princeton, New Jersey, ranging from Senior Accountant to Senior
Manager, Financial Analysis. Ms. LaViscount began her career in
public accounting with Ernst & Young.
Caroline B. Manogue
has served as Executive Vice President, Chief Legal Officer and Secretary since April 2004 and was previously Senior Vice President, General Counsel and Secretary since September 2000. Prior to joining Endo, Ms. Manogue was an Associate at the law firm Skadden, Arps, Slate, Meagher & Flom LLP since 1995.
Charles A. Rowland,
Jr. was appointed Executive Vice President, Chief
Financial Officer and Treasurer on December 6, 2006. Mr. Rowland has
more than 20 years of pharmaceutical industry experience. Most
recently, he served as Senior Vice President and CFO of Biovail
Pharmaceuticals, Inc., a specialty pharmaceutical company. Before
joining Biovail in 2004, he had served since 2001 as Chief Operating
and Financial Officer for Breakaway Technologies, a management
consulting company. His pharmaceutical industry career includes
positions of increasing scope and responsibility at Pharmacia Corp.,
where he had global responsibility for Finance and Information
Technology for the Pharmaceutical Business and financial
responsibility for the Global Supply organization as Vice President,
Finance Global Supply and VP Finance & IT- Global Pharma Ops;
Novartis Pharmaceuticals Corp., where he was VP, Planning and
Decision Support, and Bristol-Myers Squibb, where he served as
Director of Finance. Mr. Rowland began his career in 1980 at United
Brands Inc.
Nancy J. Wysenski was
appointed Chief Operating Officer on September 6, 2007. Ms.
Wysenski, a 20-year veteran of the health care industry, most
recently was the President of EMD Pharmaceuticals, Inc., the U.S.
subsidiary of Germany-based Merck KGaA. Prior to joining and
co-founding EMD as Vice President of Marketing and Sales in 1999,
Ms. Wysenski was the Senior Vice President of Operations at
NetGenics, a venture capital-backed, start-up company specializing
in technologies for drug discovery. Prior to that, Ms. Wysenski
held a number of positions of increasing scope and responsibility at
Astra Merck, culminating as Vice President of Sales. During her
tenure at Astra Merck, she also served on the company’s operating
board. Prior to joining Astra Merck in 1990, she began her
pharmaceutical industry career in 1984 at Merck Human Health where
she held various positions of increasing responsibility.
|
